Docstoc

Biotechnology in Belgium - Market Research Report

Document Sample
Biotechnology in Belgium - Market Research Report Powered By Docstoc
					Biotechnology in Belgium - Market Research Report
For more details on the content of report and ordering information please visit:

http://www.aarkstore.com/reports/Biotechnology-in-Belgium-32122.html

Introduction

Biotechnology in Belgium industry profile provides top-line qualitative and quantitative
summary information including: market size (value 2007-11, and forecast to 2016). The profile
also contains descriptions of the leading players including key financial metrics and analysis of
competitive pressures within the market. Essential resource for top-line data and analysis
covering the Belgium biotechnology market. Includes market size data, textual and graphical
analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*AstraZeneca PLC

*The biotechnology market consists of the development, manufacturing and marketing of
products based on advanced biotechnology research. The market value reflects revenues of
companies within this industry from product sales, licensing fees, royalties and research
funding. Any currency conversions used in the creation of this report have been calculated
using constant 2011 annual average exchange rates.

*The Belgian biotechnology market had total revenues of $6.8 billion in 2011, representing a
compound annual growth rate (CAGR) of 10.5% between 2007 and 2011.

*The medical/healthcare segment was the market's most lucrative in 2011, with total revenue
of $5.3 billion, equivalent to 77.5% of the market's overall value.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players
in the biotechnology market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore
attractiveness of the biotechnology market in Belgium

Leading company profiles reveal details of key biotechnology market players’ global operations
and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the
Belgium biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Belgium economy

Key Questions Answered

What was the size of the Belgium biotechnology market by value in 2011?

What will be the size of the Belgium biotechnology market in 2016?

What factors are affecting the strength of competition in the Belgium biotechnology market?

How has the market performed over the last five years?


Table of Contents :


Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 14
New entrants 15
Threat of substitutes 16
Degree of rivalry 17
Leading Companies 18
AstraZeneca PLC 18
Novartis AG 22
Sanofi SA 25
ThromboGenics NV 28
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related MarketLine research 32

LIST OF TABLES
Table 1: Belgium biotechnology market value: $ billion, 2007–11 8
Table 2: Belgium biotechnology market category segmentation: $ billion, 2011 9
Table 3: Belgium biotechnology market geography segmentation: $ billion, 2011 10
Table 4: Belgium biotechnology market value forecast: $ billion, 2011–16 11
Table 5: AstraZeneca PLC: key facts 18
Table 6: AstraZeneca PLC: key financials ($) 19
Table 7: AstraZeneca PLC: key financial ratios 20
Table 8: Novartis AG: key facts 22
Table 9: Novartis AG: key financials ($) 23
Table 10: Novartis AG: key financial ratios 23
Table 11: Sanofi SA: key facts 25
Table 12: Sanofi SA: key financials ($) 26
Table 13: Sanofi SA: key financials (€) 26
Table 14: Sanofi SA: key financial ratios 26
Table 15: ThromboGenics NV: key facts 28
Table 16: Belgium size of population (million), 2007–11 29
Table 17: Belgium gdp (constant 2000 prices, $ billion), 2007–11 29
Table 18: Belgium gdp (current prices, $ billion), 2007–11 29
Table 19: Belgium inflation, 2007–11 30
Table 20: Belgium consumer price index (absolute), 2007–11 30
Table 21: Belgium exchange rate, 2007–11 30

LIST OF FIGURES
Figure 1: Belgium biotechnology market value: $ billion, 2007–11 8
Figure 2: Belgium biotechnology market category segmentation: % share, by value, 2011 9
Figure 3: Belgium biotechnology market geography segmentation: % share, by value, 2011 10
Figure 4: Belgium biotechnology market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the biotechnology market in Belgium, 2011 12
Figure 6: Drivers of buyer power in the biotechnology market in Belgium, 2011 13
Figure 7: Drivers of supplier power in the biotechnology market in Belgium, 2011 14
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in
Belgium, 2011 15
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Belgium,
2011 16
Figure 10: Drivers of degree of rivalry in the biotechnology market in Belgium, 2011 17
Figure 11: AstraZeneca PLC: revenues & profitability 20
Figure 12: AstraZeneca PLC: assets & liabilities 21
Figure 13: Novartis AG: revenues & profitability 23
Figure 14: Novartis AG: assets & liabilities 24
Figure 15: Sanofi SA: revenues & profitability 27
Figure 16: Sanofi SA: assets & liabilities 27